Regenxbio
RGNX
174 hedge funds and large institutions have $705M invested in Regenxbio in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 59 increasing their positions, 66 reducing their positions, and 23 closing their positions.
98% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $761K
5.81% more ownership
Funds ownership: 79.25% → 85.06% (+5.8%)
3% less funds holding
Funds holding: 180 → 174 (-6)
9% less capital invested
Capital invested by funds: $778M → $705M (-$72.6M)
11% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 66
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$30M |
| 2 |
Millennium Management
New York
|
+$15.4M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$13.4M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.31M |
| 5 |
JP Morgan Chase
New York
|
+$4.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$41.9M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$6.04M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.75M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.5M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$3.44M |
RGNX Hedge Fund Activity: Q1 2023 in Review
174 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q1 2023, worth a combined $705M — down 9.3% from $778M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of RGNX and 19 opened new positions — a net loss of 4 holders — while 66 trimmed existing stakes and 59 added.
The largest buyer was BlackRock, adding an estimated $30M. The largest seller was RTW Investments, exiting entirely with an estimated $41.9M sold.
- 174 institutional investors held Regenxbio (RGNX) as of Q1 2023, down from 180 in Q4 2022.
- Funds reported $705M of Regenxbio stock for Q1 2023, down 9.3% quarter-over-quarter.
- 19 funds opened new Regenxbio positions in Q1 2023 and 23 closed out, a net change of -4 holders.
- The largest Regenxbio buyer in Q1 2023 was BlackRock, an estimated $30M added.
- The largest Regenxbio seller in Q1 2023 was RTW Investments, an estimated $41.9M sold.
Based on aggregated 13F filings for Q1 2023.